New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.

Melatonin prolonged-release tablets (Slenyto, Flynn Pharma) are the first oral melatonin formulation to be approved for use in children. Slenyto is indicated for the treatment of insomnia in children and adolescents (2 to 18 years old) with autism spectrum disorder (ASD) and/or Smith-Magenis syndrome (SMS), where sleep hygiene measures have been insufficient.

This review is older than 18 months; in view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature.

NICE has accredited the process used by the Regional Drug and Therapeutics Centre to produce New Drug Evaluations. Accreditation is valid until the 30th of June 2024.
For more information visit www.nice.org/accreditation